{"entity":{"id":"nct04782687","kind":"trial","name":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of Selinexor, Daratumumab, Lenalidomide in multiple myeloma, run by US Oncology Research, active and no longer recruiting.","summary":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma is a phase 2 interventional study registered as NCT04782687 by US Oncology Research, with 73 participants enrolled, started 2021-09-10 and due to reach its primary completion in 2026-05-31. Interventions recorded: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide. Conditions listed: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04782687","url":"https://clinicaltrials.gov/study/NCT04782687"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["kinase-inhibitors","monoclonal-antibody","protac-degrader"],"targets":[],"drugs":["selinexor","daratumumab","lenalidomide"],"companies":["mckesson-us-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04782687","phase":"2","setting":"A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma","sponsor":"US Oncology Research","started":"2021-09-10","startedType":"actual","enrolled":73,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04782687/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/"}],"company":[{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","route":"/companies/mckesson-us-oncology/"}]}}